Benefits
Postprandial Glucose Spike Reduction
In a crossover RCT, Reducose® with 50 g maltodextrin cut glucose iAUC by about 14% at 250 mg and about 22% at 500 mg, with insulin iAUC down about 24% at both doses, versus placebo. A separate RCT that added mulberry leaf extract to 75 g sucrose cut glucose iAUC by about 42% and insulin iAUC by about 40%. Effects are most pronounced acutely with carbohydrate-containing meals.
Postprandial Insulin Reduction
By blunting glucose spikes, mulberry extract reduces the corresponding insulin response. This may benefit insulin-resistant individuals and those targeting metabolic flexibility. Trials show proportional reductions in insulin AUC.
Post-Meal Blood-Sugar Support in Glucose-Intolerant Adults
An RCT in impaired-glucose-tolerance patients showed glucose suppression. In a 12-week T2DM trial, 300 mg twice daily improved HDL cholesterol, insulin, and MDA (oxidative stress) but did not significantly affect other metabolic markers. A systematic review supports modest postprandial glucose effects but notes evidence-quality limitations.
Carbohydrate Digestion Modulation
By inhibiting α-glucosidase enzymes, mulberry extract reduces digestion of complex carbohydrates and disaccharides (sucrase, maltase, isomaltase). This is the same mechanism as the prescription drug acarbose (Precose®), though mulberry extract has less potent and shorter-duration effects.
Weight Management Adjunct (Speculative)
By reducing postprandial glucose/insulin spikes, mulberry extract may indirectly support weight management — particularly in carbohydrate-heavy diets. Direct weight-loss RCTs with mulberry as primary intervention are limited; treat as a metabolic adjunct rather than weight-loss agent.
Mechanism of action
α-Glucosidase Inhibition (DNJ)
1-Deoxynojirimycin (DNJ) is an iminosugar that competitively inhibits intestinal α-glucosidases (sucrase, maltase, isomaltase). This slows the conversion of disaccharides and starch to absorbable monosaccharides, reducing the speed and magnitude of glucose absorption. Mulberry extract 1000-fold diluted has been shown to inhibit sucrase 96%, maltase 95%, isomaltase 99%.
Reduced Postprandial Glucose Excursion
By delaying carbohydrate digestion, mulberry extract flattens the postprandial glucose curve — both reducing peak glucose and delaying its time-to-peak. This directly mimics acarbose's mechanism of action, though with different potency profile and food synergies.
Reduced Insulin Demand
Lower glucose excursions trigger smaller insulin responses. Over time, reduced insulin demand may help preserve beta-cell function and reduce insulin-driven processes (lipogenesis, hunger signaling). Trials documented proportional insulin AUC reductions alongside glucose effects.
Possible GLUT4 Translocation Effects
Beyond α-glucosidase inhibition, gallic acid in mulberry leaves shows GLUT4 translocation effects in vitro — potentially enhancing peripheral glucose disposal independent of insulin. This adds a second mechanism beyond intestinal absorption blockade.
Antioxidant and Anti-Inflammatory Activity
Mulberry leaf phenolics (quercetin, kaempferol, rutin, chlorogenic acid) provide antioxidant and anti-inflammatory effects in vitro and in animal models. A T2DM trial showed reduced MDA (a lipid peroxidation marker), consistent with this mechanism.
Clinical trials
Double-blind, randomized, repeat-measure phase 2 crossover trial at Functional Food Centre, Oxford Brookes University. Three doses of mulberry-extract (Reducose® 5% DNJ — 125 mg, 250 mg, 500 mg) vs. placebo with 50 g maltodextrin in normoglycaemic healthy adults. (Lown, Fuller, Lightowler, Fraser, Gallagher, Stuart, PLoS One)
37 normoglycaemic healthy adults aged 19-59, BMI 20-30 kg/m². Crossover design.
Significant dose-dependent reductions in postprandial glucose (pIAUC) and insulin (pIAUC) over 120 minutes vs. placebo. Mulberry extract was well tolerated. Established Reducose® dose-response for glucose-spike reduction.
Randomized, double-blind clinical trial of standardized extract from Morus alba leaves (SEMA). α-glucosidase inhibitory effect compared to acarbose; acute oral toxicity assessment; clinical evaluation in patients with impaired glucose tolerance. (Hwang, Li, Lim, Wang, Hong, Evid Based Complement Alternat Med)
Patients with impaired glucose tolerance (IGT). Animal toxicology + human clinical phases.
SEMA inhibited α-glucosidase at 4× higher levels than acarbose (positive control) in vitro, in concentration-dependent manner. Blood glucose suppression demonstrated in vivo and in IGT patients. Safe at tested doses without observable toxicity in 14-day animal observation.
Randomized, double-blind, placebo-controlled trial of Morus alba extract (300 mg twice daily) vs. placebo for 12 weeks in patients with type 2 diabetes mellitus. Primary outcomes: liver enzymes, inflammation/oxidative stress biomarkers, insulin metabolism, lipid profiles. (Taghizadeh M, Mohammad Zadeh A, Asemi Z, Farrokhnezhad AH 2022, Clin Nutr ESPEN)
60 patients with T2DM (30 per arm). 12-week intervention.
12-week Morus alba extract had beneficial effects on HDL cholesterol, insulin, and MDA (malondialdehyde — oxidative stress marker) vs. placebo, but did not affect other metabolic profiles (fasting glucose, total cholesterol, LDL, triglycerides). Limited effect size; supports mulberry as a potential adjunct rather than primary diabetes intervention.